Leading The Way In Anti-cancer Drug Discovery & Development

Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of promising treatments for the future.

The content listed here is representative of US-based studies.  For a full listing of all Taiho studies globally, please see the following.

Taiho Pharmaceutical Company

Filter view:
P
Preclinical
1
Phase 1
2
Phase 2
3
Phase 3
S
Submitted
F
Filed
Compounds Ind
Code
Indications
Location
Phase
TAS-102
Gastric Cancer
US, EU, JP
P
1
2
3
F

TAS-102 is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor.

TAS-114
SOLID TUMORS
US, EU, JP
P
1
2
3
F
TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism. It is a fluoropyrimidine modulator with the potential to increase the activity of 5-FU-based anti-cancer drugs. It is being developed in combination with S-1 and capecitabine.
TAS-119
SOLID TUMORS
US, EU
P
1
2
3
F
TAS-119 is a highly selective Aurora A inhibitor (selective over Aurora B & C). TAS-119 has the potential to enhance anti-tumor activity of taxanes through activation of the spindle assembly checkpoint.
TAS-120
SOLID TUMORS
US, EU, JP
P
1
2
3
F
TAS-120 is the first covalent FGFR inhibitor that will be tested in clinic and has the potential to selectively inhibit tumor growth of cancer cells with FGFR abnormalities.
TAS3681
SOLID TUMORS-mCRPC
US, EU
P
1
2
3
F
TAS3681, a pure AR antagonist, is specifically designed to address the unmet medical need in CRPC patients by combining known mechanisms of action with novel ones:
  • A selective AR antagonist suppressing transactivation of both wild-type and mutated (including F876L) cell lines and inhibiting AR translocation to the nucleus
  • DownregulatingAR expression in prostate cancer cells in vitro and in vivo and effectively suppressing androgen independent AR transactivation by outlaw pathways
  • Driving AR downregulation of full-length androgen receptor (FL-AR) and AR splice variants (eg, AR-v7) in vitro and in vivo, and suppressing AR dependent and AR-v7 dependent cell growth
TAS4464
Solid tumors, Hematological cancer
US, EU, JP
P
1
2
3
F
TAS4464 is a highly potent and selective NEDD8 activating enzyme inhibitor. TAS4464 has the potential to demonstrate antitumor activity through the accumulation of cullin RING ligase substrates.

Link to clinicaltrials.gov

TAS-116
Study 116 Solid tumors
US, EU
P
1
2
3
F
TAS-116 is a highly potent oral HSP90 inhibitor with unique tissue distribution properties. TAS-116 has the potential to demonstrate antitumor activity, while being designed to limit certain adverse events by unique tissue distribution.
P
Preclinical
1
Phase 1
2
Phase 2
3
Phase 3
S
Submitted
F
Filed

PLEASE NOTE: all data is current as of March 31, 2018

* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country's Regulatory Authority. In addition, the clinical efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to